Trial Profile
A Phase I Study Of UCN-01 In Combination With Gemcitabine In Unresectable Or Metastatic Pancreatic Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; UCN 01 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 30 Jan 2013 New trial record